American Century Companies Inc. Purchases 58,144 Shares of Aurinia Pharmaceuticals Inc $AUPH

American Century Companies Inc. raised its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 33.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 229,734 shares of the biotechnology company’s stock after purchasing an additional 58,144 shares during the quarter. American Century Companies Inc. owned about 0.17% of Aurinia Pharmaceuticals worth $1,847,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of AUPH. GF Fund Management CO. LTD. purchased a new stake in Aurinia Pharmaceuticals during the fourth quarter worth $27,000. Tower Research Capital LLC TRC raised its position in shares of Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $31,000. GAMMA Investing LLC raised its position in shares of Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,744 shares during the last quarter. Finally, USA Financial Formulas acquired a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at about $50,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on AUPH. Royal Bank Of Canada raised their price objective on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. HC Wainwright reiterated a “buy” rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $12.00.

Aurinia Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ:AUPH opened at $11.99 on Tuesday. The company has a market capitalization of $1.58 billion, a PE ratio of 27.88 and a beta of 1.26. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a twelve month low of $6.42 and a twelve month high of $12.53. The firm has a 50 day simple moving average of $9.98 and a 200-day simple moving average of $8.71.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). The company had revenue of $70.01 million for the quarter, compared to analysts’ expectations of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Insider Buying and Selling at Aurinia Pharmaceuticals

In related news, Director Kevin Tang acquired 200,000 shares of Aurinia Pharmaceuticals stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average price of $11.68 per share, for a total transaction of $2,336,000.00. Following the transaction, the director owned 11,329,500 shares of the company’s stock, valued at $132,328,560. This represents a 1.80% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders have purchased 1,300,000 shares of company stock worth $13,590,000. 12.20% of the stock is currently owned by insiders.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.